Company news

Phio Pharmaceuticals Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4

September 15, 2021

Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021

August 30, 2021

Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches

June 3, 2021

Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

May 12, 2021

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells

May 10, 2021

Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings

April 28, 2021

Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

April 9, 2021

Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update

March 24, 2021

Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies

February 28, 2021

Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

February 16, 2021

Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

February 11, 2021

Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market

January 24, 2021

Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market

January 20, 2021

Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update

November 9, 2020

Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment

November 8, 2020

Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 25, 2020

Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity

May 28, 2020

Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

May 11, 2020

Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market

March 30, 2020

Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth

March 30, 2020

Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update

March 25, 2020

Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene

March 9, 2020

Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering

February 12, 2020

Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

February 10, 2020

Phio Pharmaceuticals Announces Compliance with Nasdaq Listing Requirements

February 9, 2020

Phio Pharmaceuticals Announces $1.74 Million Registered Direct Offering Priced At-the-Market

February 4, 2020

Phio Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders

December 12, 2019

Phio Pharmaceuticals and Karolinska Institutet Expand Collaboration to Develop Self-Delivering RNAi Immunotherapies for Treating Solid Tumors

November 20, 2019

Phio Pharmaceuticals Announces Closing of Public Offering of Common Stock

November 19, 2019

Phio Pharmaceuticals Announces Pricing of $1.0 Million Public Offering of Common Stock

November 17, 2019

Phio Pharmaceuticals Announces Proposed Public Offering of Common Stock

November 12, 2019

Phio Pharmaceuticals Announces Adjournment of 2019 Annual Meeting of Stockholders

October 10, 2019

Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy

September 8, 2019

Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights

May 13, 2019

Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer

April 9, 2019

← Newer news releases

Decks

The 5 newest of 9 decks. Every deck is listed under its year.